Company Search:
Advanced Search
Sponsored Links
Replek AD Skopje Company Snapshot
Replek AD Skopje operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Replek AD Skopje with three other pharmaceutical manufacturers in Europe: Dbv Technologies of France (2018 sales of 14.54 million Euro [US$15.99 million] of which 100% was Research & Development), Photocure ASA of Norway (181.51 million Norwegian Kroner [US$19.76 million] of which 61% was Hexvix/Cysview Own Sales), and Amryt Pharma Holdings Ltd which is based in the United Kingdom (£12.80 million [US$16.45 million] of which 100% was Commercial).

Sales Analysis. Replek AD Skopje reported sales of 974.74 million Denar (US$17.44 million) for the year ending December of 2018. This represents an increase of 2.0% versus 2017, when the company's sales were 955.23 million Denar. This was the third consecutive year of growth at Replek AD Skopje.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Replek AD Skopje
  Stock Performance Chart for Replek AD Skopje
  Stock Data: Recent Stock Performance:
  Current Price (11/12/2019): 76,923
(Figures in Denar)
1 Week 0.0%   13 Weeks -0.7%  
4 Weeks 3.3%   52 Weeks n/a  
Replek AD Skopje Key Data:
  Ticker: REPL Country: Macedonia
  Exchanges: Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2018 Sales 974,739,000
(Year Ending Jan 2019).
Employees: 352
  Currency: Denar Market Cap: 1,993,844,160
  Fiscal Yr Ends: December Shares Outstanding: 25,920
  Share Type: Closely Held Shares: 3,429
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.